ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ÍõÖÇÍŶÓÓëÏàÖúÕßÕ¹ÏÖÁÛ×´ÉÏƤ¶ñÐÔת»¯Òªº¦µ÷¿Ø»úÖƺÍÖÎÁÆаеã

¸å¼þȪԴ£º£º£ºÁ¥Êô¿ÚǻҽԺ ±à¼­£º£º£ºÀîͯÖÛ¡¢¡¢¡¢Íõ¶¬Ã· ÉóºË£º£º£ºÏÄçø ÔĶÁÁ¿£º£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøѶ£¨Í¨Ñ¶Ô±Â¬»Á×Ì£©¿ÚÇ»ÁÛ״ϸ°û°©£¨OSCC£©ÊÇÍ·¾±²¿ÁÛ״ϸ°û°©µÄÖ÷ÒªÀàÐÍ£¬£¬£¬¶ñÐԳ̶ȸߣ¬£¬£¬ÈÝÒ×ÔÚÔçÆÚ¼´±¬·¢¾±ÁÜ°ÍתÒÆ¡£ËäÈ»¿ÚÇ»ÁÛ°©µÄÖÎÁÆÒѾ­¿ªÕ¹ÎªÒÔÊÖÊõΪÖ÷£¬£¬£¬Á¬Ïµ·Å»¯ÁÆ¡¢¡¢¡¢°ÐÏòÖÎÁƺÍÃâÒßÖÎÁƵÄ×ÛºÏÖÎÁÆ·½Ê½£¬£¬£¬µ«Æä5ÄêÉúÑÄÂÊÈÔԼΪ50%¡£¹ØÓÚÖÐÍíÆÚ¿ÚÇ»ÁÛ°©£¬£¬£¬ÆäÔ¤ºóÔòÏÔÖø½µµÍ£¬£¬£¬Í¬Ê±ÅãͬÈÝò¸Ä±ä¡¢¡¢¡¢ÍÌÑÊÓïÒô¹¦Ð§ÕÏ°­µÈ²¢·¢Ö¢£¬£¬£¬ÑÏÖØÓ°ÏìÉúÑÄÖÊÁ¿¡£¿£¿£¿ÚÇ»ÁÛ°©ÊÇÒ»ÖÖ¾ßÓжà½×¶Î½¥½ø¶ñ±äÌØÕ÷µÄ¶ñÐÔÖ×Áö£¬£¬£¬¿É´ÓÕý³£ð¤Ä¤-°©Ç°²¡±ä-°©Ñݱä¶øÀ´£¬£¬£¬ÆäÖпÚÇ»°×°ß£¨OLK£©ÊÇ×î³£¼ûµÄ¿ÚÇ»°©Ç°²¡±ä£¬£¬£¬Ñо¿Åú×¢£¬£¬£¬¿ÚÇ»°×°ß¶ñ±äÂÊ¿É´ï11.7-23.1%¡£Òò´Ë£¬£¬£¬ÈôÄÜÔÚ°©Ç°²¡±ä½×¶ÎÊ©¼Ó¸ÉÔ¤²½·¥£¬£¬£¬Ôò¿ÉÓÐÓÃÔ¤·À¿ÚÇ»ð¤Ä¤°©±ä£¬£¬£¬Ìá¸ß»¼ÕßÉúÑÄÂʺÍÉúÑÄÖÊÁ¿¡£½üÄêÀ´£¬£¬£¬ÒÔ¿¹PD-1¿¹ÌåΪ½¹µãµÄÃâÒßÖÎÁÆÔÚÈ«Éí¶àÖÖÖ×ÁöÖÎÁÆÖÐÈ¡µÃÖ÷ҪϣÍû£¬£¬£¬µ«ÔÚ¿ÚÇ»ÁÛ°©ÖÐÓ¦´ðÂʲ»µ½20%£¬£¬£¬ÌáÐѱ£´æÆäËüÃâÒßÌÓÒÝ;¾¶¡£Òò´Ë£¬£¬£¬ÐèÒª¶Ô¿ÚÇ»°©±äÀú³ÌÖÐ΢ÇéÐÎÖÐϸ°ûÀàÐͺÍÂþÑܵĶ¯Ì¬×ª±ä¾ÙÐÐÖÜÈ«µÄ±íÕ÷£¬£¬£¬Ñ°ÕÒ¸ÃÀú³ÌÖн鵼ÃâÒßÌÓÒݵÄÒªº¦·Ö×Ó£¬£¬£¬Îª¿ÚÇ»ÁÛ°©µÄÖÎÁÆÌṩеİеã¡£

2022Äê8ÔÂ16ÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·Á¥Êô¿ÚǻҽԺµÄÍõÖǽÌÊÚÁªºÏ±±¾©´óѧÉúÎïҽѧǰÑØÁ¢ÒìÖÐÐÄ£¨BIOPIC£©µÄ°×·²½ÌÊÚÔÚJournal of Clinical InvestigationÔÓÖ¾ÔÚÏß½ÒÏþÌâΪTDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinomaµÄÑо¿ÂÛÎÄ¡£¸ÃÑо¿ÒÔ¿ÚÇ»°×°ßºÍ¿ÚÇ»ÁÛ°©»¼ÕßΪÑо¿¹¤¾ß£¬£¬£¬½èÖúµ¥Ï¸°ûת¼×é²âÐò¡¢¡¢¡¢µ¥Ï¸°ûTCR²âÐò£¬£¬£¬Á¬ÏµÌåÍâ¼°ÌåÄÚʵÑ飬£¬£¬ÏµÍ³Ãè»æÁË¿ÚÇ»ð¤Ä¤°©±äÀú³ÌÖÐCD4+/CD8+ Tϸ°û¡¢¡¢¡¢Ëèϵϸ°û¡¢¡¢¡¢ÖÐÐÔÁ£Ï¸°ûºÍ»ùÖÊϸ°ûµÄ¶¯Ì¬×ª±äͼÆס£Í¨¹ýµ¥Ï¸°û²âÐòÆÊÎö£¬£¬£¬·¢Ã÷»ùÖÊϸ°ûÖб£´æһȺTDO2+¼¡³ÉÏËάϸ°ûÑÇȺ£¬£¬£¬Î»ÓÚ°©³²ÍâΧ£¬£¬£¬¾ßÓнÏÇ¿µÄTϸ°ûÇ÷»¯¹¦Ð§£¬£¬£¬È»¶øÇ÷»¯¶øÀ´µÄCD4+/CD8+ Tϸ°û·ºÆðÏÔ×ŵÄÃâÒßÒÖÖÆ״̬£¬£¬£¬Í¨¹ýÌåÍâÇõͻòÌåÄÚÒÖÖƸü¡³ÉÏËάϸ°ûÑÇȺÖÐTDO2±í´ï¿ÉÓÐÓÃÄæתTϸ°ûÃâÒßÒÖÖÆ״̬£¬£¬£¬ÌáÐѸÃȺ¼¡³ÉÏËάϸ°û¿ÉÄÜÔÚ°©³²ÍâΧÐÞ½¨¡°ÏÝÚ塱£¬£¬£¬²¢Í¨¹ýTDO2-AhRÐźÅÖáÓÕµ¼Tϸ°ûÃâÒßÒÖÖÆ£¬£¬£¬Ôö½øÖ×ÁöÃâÒßÌÓÒÝ¡£±¾Ñо¿Õë¶Ô¿ÚÇ»ÁÛ°©µÄÃâÒßÌÓÒÝÌá³öÁËеĻúÖÆ£¬£¬£¬ÎªÔçÆÚ×è¶Ï¿ÚÇ»ð¤Ä¤°©±äÀú³Ì¡¢¡¢¡¢Ìá¸ß¿ÚÇ»°©ÃâÒßÖÎÁÆÓÐÓÃÐÔÌṩÁËеİеã¡£


8841A4CA8D861582D2883F36F2F_5E1E4BD9_ED26

ͼ1 TDO2+¼¡³ÉÏËάϸ°û½éµ¼CD4+/CD8+ Tϸ°ûÃâÒßÒÖÖÆ£¬£¬£¬´ÙÈë¿ÚÇ»ð¤Ä¤°©±äÀú³ÌʾÒâͼ


ngµç×ÓÓÎÏ·Á¥Êô¿ÚǻҽԺµÄÍõÖǽÌÊÚÒÔ¼°±±¾©´óѧÉúÎïҽѧǰÑØÁ¢ÒìÖÐÐÄ£¨BIOPIC£©¡¢¡¢¡¢±±¾©Î´À´»ùÒòÕï¶Ï¸ß¾«¼âÖÐÐÄ£¨ICG£©¡¢¡¢¡¢ÉúÃü¿ÆѧѧԺ°×·²½ÌÊÚÊDZ¾ÎĵÄÅäºÏͨѶ×÷Õß¡£±±¾©´óѧBIOPIC¡¢¡¢¡¢Ç°Ñؽ»Ö¯Ñ§¿ÆÑо¿ÔºµÄ²©Ê¿Ñо¿Éúºú˼ÃΡ¢¡¢¡¢ngµç×ÓÓÎÏ·Á¥Êô¿ÚǻҽԺµÄ¬»Á×̲©Ê¿¡¢¡¢¡¢Ð»ÎÄÇ¿²©Ê¿ºÍÍõµÏÙ©²©Ê¿ÊDZ¾ÎĵÄÅäºÏµÚÒ»×÷Õß¡£

ÂÛÎÄÁ´½Ó£º£º£ºhttps://www.jci.org/articles/view/157649


¡¾ÍøÕ¾µØͼ¡¿